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Abstract 
Objective:  Describe the role and integration of ambulatory care pharmacists in a Human Immunodeficiency Virus (HIV) clinic within a 
free and bilingual clinic with regards to types of interventions made during the patient-pharmacist visit. 
Design: Retrospective, single-centered, chart review.  
Setting:  Free, bilingual clinic in Richmond, VA.  
Participants: Thirty-two adult patients with diagnosed HIV receiving care in the clinic between June 30, 2010 and January 26, 2011. 
Main Outcome Measure:  Types of interventions documented during the patient-pharmacist visit, categorized as medication review, 
patient education, or adherence monitoring.  
Results:  Total of 32 patients accounted for 55 patient-pharmacist visits and 296 interventions.  The most common interventions were 
medication review (66.9%), patient education (23.3%), and adherence monitoring (9.8%).  Post-hoc analysis suggests Hispanic 
patients are more likely to be diagnosed with Acquired Immune Deficiency Syndrome (AIDS) (P = 0.01), have current or history of 
opportunistic infection (OI) (P=0.01), and have current or history of OI prophylaxis (P = 0.03).  Adherence monitoring was less 
common amongst the non-Hispanics (7.1%) compared to the Hispanic sub-population (16.5%), (P = 0.04).  
Conclusion: The role of ambulatory care pharmacists in a free and bilingual clinic goes beyond adherence monitoring.  Pharmacists 
can be a valuable part of the patient care team by providing medication review and patient education for HIV and other co-
morbidities within free clinics.  Further research is warranted to assess outcomes and to further explore the underlying barriers to 
early HIV diagnosis and adherence within the Hispanic population. 
 
Introduction 
Since the worldwide outbreak of the Human 
Immunodeficiency Virus (HIV) epidemic in the early 1980s, 
there has been an increased need for antiretroviral therapy 
(ART), enhanced patient monitoring, and education regarding 
treatment and prevention for those with the disease and the 
public.  Patients infected with HIV are now living longer, 
partly due to the advances in ART.  These advances have 
significantly decreased pill burden and improved adherence.   
This has resulted in improved quality of life and survival 
rates.
1,2 
 
Pharmacists provide direct patient care within a variety of 
multidisciplinary healthcare settings.
3
 Ambulatory care 
pharmacists in HIV clinics play an integral role in optimizing 
medication therapy and improving patient outcomes when  
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working as part of a multidisciplinary team.
4,5,6,7,8,9 
 March, et 
al. described the impact of pharmacists’ interventions on 
patient outcomes in a federally funded HIV clinic in Los 
Angeles, CA.  At the conclusion of the study, patients being 
followed by the pharmacists in the clinic had a significant 
improvement in CD4 count, viral load (VL), and drug-related 
toxicities.
4 
 Although advances in ART have led to extended 
life expectancy in HIV patients, the long-term use of these 
medications has been associated with metabolic 
abnormalities which may increase the risk for developing 
chronic condition such as diabetes and dyslipidemia.
1,2,10  
Evidence supports the benefit of ambulatory care 
pharmacists providing chronic disease state management to 
both HIV and non-HIV infected patients by optimizing and 
monitoring treatment plans, educating patients and 
providers, increasing adherence rates, and promoting cost 
effective treatment.
3,4,5,11,12
 
Free clinics are a common safety-net for the uninsured to 
receive healthcare services.
13  
Based on a national survey of 
free clinics, 23.1% of free clinics provide HIV services.
14  
Literature describing the role ambulatory care pharmacists 
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working in safety-net clinics is limited mostly to Federally 
Qualified Healthcare Centers (FQHC) and community health 
centers.
3,8,15,16,17,18 
 There is an increased need to further 
describe and understand the role of ambulatory care 
pharmacists within unique practice settings, such as free 
clinics. 
 
The primary outcome of the study was to describe the role 
and integration of ambulatory care pharmacists in a HIV clinic 
within a free and bilingual clinic and describe the types of 
interventions made by the pharmacists. Secondary outcomes 
included change in CD4 count, VL, adherence rate, ART or HIV 
complications, and time spent during the patient-pharmacist 
visit.   
 
Methods 
This study was a single-centered, retrospective chart review 
in an HIV clinic within a free and bilingual clinic.  CrossOver 
Health Center is the largest freestanding clinic in Richmond, 
VA.  It has been in existence for over 25 years and provides a 
variety of free medical, laboratory, and pharmacy services for 
the qualifying uninsured population in the area.  The 
Therapeutic Intervention Preventative Services (TIPS) clinic at 
CrossOver is a Human Resources and Services Administration 
(HRSA)-funded program through the Ryan White Grant and 
was established to provide specialized care for HIV patients. 
The TIPS clinic operates three days a week and has 
approximately150 active patients.  The TIPS team is 
comprised of a medical doctor, nurse practitioner, social 
worker, and medical assistant.  In June 2010, an ambulatory 
care pharmacist practicing in academia joined the TIPS clinic 
and was later joined by a bilingual Post-Graduate Year 2 (PGY-
2) Ambulatory Care pharmacy resident in September 2010.  
During the study, the pharmacy team practiced one half day 
per week in the TIPS clinic, establishing clinical pharmacy 
services and expanding the multidisciplinary model.  The 
study was approved by the Institutional Review Board at 
Virginia Commonwealth University and by the CrossOver 
Health Center medical director, assistant medical director, 
and medical director of the TIPS clinic. 
Patients included in this study were current patients of the 
TIPS clinic of at least 18 years of age with a documented 
patient-pharmacist visit between June 30, 2010 and January 
26, 2011.   Exclusion criteria included patients who were 
pregnant or imprisoned at any time during the study period.  
Data was collected through a chart review after the study 
time period using a study specific data collection sheet 
(Appendix A).   
Patients seen in the clinic were scheduled to see either a 
medical provider for follow-up or the medical assistant for lab 
tests.  Patients were asked for verbal consent by one of the 
team members prior to the visit with the pharmacist.  A 
patient-pharmacist visit was defined as a face-to-face 
interview between the patient and the pharmacist during the 
appointment with the HIV clinic provider.  On certain 
occasions, patients were scheduled for pharmacy-only visits, 
specifically for management for other co-morbid conditions, 
adherence monitoring, and preparation of medication boxes.  
These were also considered patient-pharmacist visits. After 
the patient-pharmacist visit, the pharmacist discussed the 
patient and specific recommendations with the HIV medical 
provider.  Visit details and recommendations were also 
documented in the patient’s medical chart using a 
standardized pharmacy progress note. 
The primary outcome of the study was to describe the types 
of interventions documented by the pharmacists.  
Interventions were categorized as medication review, patient 
education, or adherence monitoring.  Only interventions that 
occurred during the patient-pharmacist visit were included in 
the study.   A visit could have one, multiple, or no 
interventions.  For the purpose of this study, medication 
review was defined as medication reconciliation; medication 
education on new or current ART or non-ART medications; 
initiating, discontinuing, or adjusting current ART or non-ART 
medication doses; assessing immunization history; or drug-
drug interaction monitoring.  Patient education included 
education on HIV, OI, co-morbidities, lifestyle changes, and 
smoking cessation.  Adherence monitoring included the 
pharmacist assisting in filling medication boxes, pharmacy 
refill monitoring, or both.   
Secondary outcomes included change in CD4 count, VL, 
adherence rate, ART and HIV complications, and time 
(minutes) spent during the patient-pharmacist visit.   As 
described in the Department of Health and Human Services 
Guidelines for the Use of Antiretroviral Agents in HIV-1-
Infected Adults and Adolescents, CD4 count is a surrogate 
marker of immune function, predictor of disease progression 
and survival, and an indicator for starting ART or 
opportunistic infection (OI) prophylaxis.
19
  VL is important in 
assessing treatment response to ART.  A low VL is associated 
with improved clinical outcomes.
19  
Change in CD4 count and 
VL from baseline was defined as the most recent documented 
value prior to the first intervention compared to the post-
intervention value defined as the last documented value after 
the patient-pharmacist visit but prior to the study end date of 
January 26, 2011.  In order to better quantify change in 
adherence rate, only patients who received pharmacist-
provided medication boxes were included in this part of the 
analysis.  In addition, the baseline self-reported rate prior to 
the first medication box fill was compared to the average of 
all adherence rates documented after the first intervention 
but prior to the study end date.  Adherence was calculated by 
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using the following formula used in the study by March, et al: 
([number of ART doses taken in a given month]/[total number 
of ART doses patient should have taken in the month])*100.
4 
   
Furthermore, change in number of ART and HIV 
complications was compared from baseline (six months prior 
to the initial intervention) to post-intervention up until the 
study end date.  An ART complication was defined as a 
documented adverse event, allergic reaction, or drug-drug 
interaction. A HIV complication was defined as an emergency 
room visit for a HIV-related cause, hospitalization, new OI, 
initiation of OI prophylaxis, or death.   
Patient demographics and characteristics such as gender, age, 
ethnicity, co-morbidities, documentation of previously failed 
ART regimen(s), diagnosis of Acquired Immune Deficiency 
Syndrome (AIDS), and history of OI diagnosis or prophylaxis 
were also documented.  Patient-specific data was de-
identified, kept in the clinic, and was accessible only by study-
approved investigators. 
A post-hoc analysis was done to compare the baseline patient 
characteristics and demographics and primary outcomes 
between the non-Hispanic and Hispanic subpopulation.  The 
definition of Hispanic used in this study was the same 
definition used by Centers for Disease Control and Prevention 
(CDC), which defines Hispanic or Latino as a person of Cuban, 
Mexican, Puerto Rican, South or Central American, or other 
Spanish culture or origin, regardless of race.
20
 
Data Analysis 
In the primary analysis, descriptive statistics including mean, 
standard deviation, and percentage were used to report 
results for baseline, primary, and secondary outcomes.  
Paired student T-test and Wilcoxon Signed Rank Test were 
used for continuous parametric and non-parametric data, 
respectively, to compare patients with documented baseline 
and post-intervention CD4 counts, VLs, and adherence rates.   
Significance was two-tailed and set at P <0.05.  During the 
study time period, there were two different assays used to 
measure VL.  At the beginning, the lower sensitivity of the 
assay was set at <48 copies.  Later on, a more sensitive assay 
was used and set at <20 copies/mL. For the purpose of the 
analysis, all VL reported as <48 copies/mL were adjusted to 
the more sensitive assay, <20 copies/mL.  In the post-hoc 
analysis, the Fisher Exact test and T-test were used for 
nominal data and continuous parametric data, respectively. 
Results 
During the study time period, there were a total of 109 
patient visits scheduled on days the ambulatory care 
pharmacists were in clinic.  Of these, 34 patients (31.2%) did 
not show up for, cancelled, or rescheduled their visits.  Of the 
75 patients who showed for their appointment, two were 
scheduled only for labs.  Therefore, the pharmacists had the 
opportunity to have a maximum of 73 patient-pharmacist 
visits during the study time period.  There were a total of 55 
(75.3%) documented patient-pharmacist visits with 32 
different patients.  Nine (28.1%) of these patients had 
multiple documented patient-pharmacist visits (range 2 – 5).   
 
Patient demographics and characteristics are specified in 
Table 1.  The mean age (±SD) of patients included in the 
analysis was 46.4 years (±10.2), and the majority of patients 
were males (62.5%) of African American descent (53.1%).  
The mean number of co-morbid conditions amongst the 
patients were 4.8 (range 0 – 11), and 40.6% of the patients 
were treatment-naïve.  Only one patient in this study had not 
been started on ART during the study time period.  
Furthermore, 53.1% of patients in this study had a diagnosis 
of AIDS and 40.6% had a current or history of an OI. 
 
Primary Outcomes 
All 32 patients were included in the primary analysis and 
accounted for a total of 296 documented interventions.  
Table 2 provides a description of subcategories within each 
type of intervention.  Medication review was the most 
common category of intervention (198/296; 66.9%).  All 
patients had at least one medication review intervention 
during each patient-pharmacist encounter.  The most 
common intervention under medication review was 
medication reconciliation and immunization 
recommendation.  Similar to medication review, all 32 
patients had at least one documented patient education 
intervention.  This accounted for 69 (23.3%) of the total 
number of interventions and 43 of all 55 visits (78.2%).  
Adherence monitoring was documented for 10 patients and 
accounted for 29 (9.8%) of all interventions.   
 
Secondary Outcomes 
In the analysis of secondary outcomes (Table 3), only patients 
with documented baseline and post-intervention CD4 count 
(n = 24) and VL count (n = 23) were included.  The average 
baseline and post-intervention CD4 counts were 444.2 
cells/mm
3 
and 496.4 cells/mm
3
, respectively.  The change in 
CD4 count was found to be statistically significant (P = 0.04).  
The average baseline and post-intervention VLs were 34,205 
copies/mL and 3,951 copies/mL, respectively.  This change in 
VL was not found to be statistically significant, (P = 0.06).   
 
There were six patients with documented baseline and post-
intervention adherence rates.  At baseline, the mean percent 
adherence rate (± SD) was 64.2% (± 50.4) and post-
intervention was 97.5% (± 4.1).  However, this increase in 
adherence rate did not achieve statistical significance, (P = 
0.16).  None of the patients in the study had a documented 
ART complication at baseline, compared to one patient at the 
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end of the study time period.  This ART complication was 
documented as mild gastrointestinal (GI) adverse effects after 
improved adherence with ART regimen post-intervention.  
Five (15.6%) patients had baseline HIV complications 
accounting for seven complications in total.  The most 
common complications were OIs, such as Pneumocystis carinii 
pneumonia (PCP) and toxoplasmosis.  There were no reports 
of new HIV complications during the study time period 
amongst the 32 patients included in this study.   
 
Of the 55 patient-pharmacist visits, visit time was 
documented for 45 visits (81.8%).  The average patient-
pharmacist visit length was 18.1 minutes (range 5 – 45 
minutes). However, this time does not take into account time 
spent reviewing the patient’s chart prior to the visit, time 
discussing the patients with clinic providers, and time 
documenting after the patient-pharmacist visit.  The 
pharmacists in this study estimate these tasks took on 
average an additional 20 – 30 minutes.  
 
Hispanic Subpopulation 
Approximately one-fifth of patients in this study were 
Hispanic (7/32) and accounted for 15 out of the 55 patient-
pharmacist visits during the study time period.  In addition, 
four out of the seven Hispanic patients had their patient-
pharmacist visit conducted in Spanish by the bilingual 
pharmacist.  Based on the baseline patient characteristics and 
demographics results of the post-hoc analysis (Table 1), the 
non-Hispanic subpopulation was less likely to have a 
diagnosis of AIDS (40% versus 100%, P = 0.01), current or 
history of OI (28% versus 85.7%, P = 0.01), and current or 
history of OI prophylaxis (52% versus 100%, P = 0.03) 
compared to the Hispanic subpopulation.  
 
Eight-five (28.7%) of the 296 total interventions occurred 
within the Hispanic subpopulation, (Table 2).  Medication 
review (67.8% versus 64.7%, P = 0.94) and patient education 
(25.1% versus 18.8%, P =0.45) were similar between the non-
Hispanic and Hispanic subpopulations. However, in the post-
hoc analysis the Hispanic subpopulation was statistically more 
likely to receive adherence monitoring compared to the non-
Hispanic subpopulations, 16.5% versus 7.1%, P = 0.048.   
 
Within the Hispanic subpopulation there was no statistically 
significant change in CD4 count (P = 0.44), VL (P = 0.32), and 
adherence rate (P = 0.39). The small number of Hispanic 
patients with documented baseline and post-intervention 
CD4 counts, VLs, and adherence rates limited the ability to 
compare the differences between the non-Hispanic and 
Hispanic subpopulation.  
 
 
Discussion 
Pharmacists are the medication experts within the healthcare 
field and often times one of the last healthcare professionals 
patients see before taking their medication.  Ambulatory care 
pharmacists practicing in HIV clinics have traditionally worked 
closely with other healthcare professionals to improve 
medication adherence with ART.
3,4,6,7,9,12  
Patients with HIV 
are often vulnerable to having poor medication adherence, 
which could be attributed to increased pill burden, adverse 
effects from ART, lack of disease and medication education, 
and low threshold between non-adherence and risk of 
developing resistance to ART.
1,2,19
 
 
The results of this study help to better define the patient-
pharmacist visit in an HIV clinic.  In this study, a patient-
pharmacist visit had one or multiple types of interventions.  
The most common type of intervention was medication 
review, followed by patient education, and adherence 
monitoring. The pharmacists in this study were able to 
document 296 interventions in 55 patient-pharmacist visits. 
The pharmacists provided on average five interventions 
during each patient-pharmacist within a relatively short visit 
of approximately 18 minutes.  Aside from the patient-
pharmacist visits, the pharmacists in this study also served as 
a drug information resource to clinic providers and were 
available for consults for patient or non-patient specific 
medication or disease state management questions. 
 
Prior to the start of the service, it was believed the role of the 
pharmacists within the team would be adherence monitoring 
and providing medication boxes for patients.  Adherence 
monitoring interventions seen during the data collection time 
were less frequent than what was originally anticipated.  
However, a patient who received an adherence monitoring 
intervention was more likely to be scheduled for a   
pharmacist-only visit and have multiple patient-pharmacists 
visits during the study time period.   Throughout the study 
time period, it was also noted that interventions were more 
focused on medication review and patient education, which 
extended beyond HIV, ART, and OIs. 
 
In this study, the number of patients were similar to those in 
the study by March, et al.
4  
In both studies, the changes in 
CD4 count were found to be statistically significant. The 
preliminary results of this study for change in VL and 
adherence rates were not statistically significant.  However, 
there appears to be a trend towards improved VL and 
adherence rate after the patient-pharmacist visit. The 
Department of Health and Human Services HIV treatment 
guidelines suggest adherence of up to 95% may be necessary 
to prevent resistance to ART and virologic failure.
19
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Therefore, the increase in adherence rate from 64.2% at 
baseline to 97.5% post-intervention may appear to be 
clinically significant.
  
This data may suggest the positive 
impact ambulatory care pharmacists may have in increasing 
adherence rate when added to an HIV multidisciplinary team. 
 
A post-hoc analysis was performed to compare the non-
Hispanic and Hispanic subpopulations in this study.  Hispanics 
in the United States account for more than 19% of new HIV 
diagnosis, making them the second most common ethnic 
group of new cases of HIV after African Americans.
21 
  
 
According to the U.S. Census Bureau of 2009, Hispanics are 
the fastest growing ethnic group in this country and account 
for 15.8% of the total U.S. population as well as over a 
quarter of the country’s population living below the federal 
poverty level.
22,23  
In Richmond, VA, Hispanics represent 6.3% 
of the city’s total population, which is a 95% growth in the 
Hispanic population since 2000.
24 
 However, an alarming 38% 
of Hispanics living in Richmond live below the federal poverty 
line, a number that is disproportionately higher than the 
national average.
24,25
  A national survey of free clinics 
estimates that Hispanics represent 25.1% of patients seen in 
these types of clinics.
14
  In this study, the number of Hispanic 
patients (21.9%) represented a larger percentage of the 
Hispanic population from what is estimated in the city of 
Richmond and even the country.  However, it is similar to the 
number of Hispanics patients receiving care within free clinics 
making this a unique ethnic group to further analyze within 
the context of this study. 
 
In the post-hoc analysis, the Hispanic subpopulation all had a 
confirmed diagnosis of AIDS, and most had a current or 
history of an OI.  These findings were consistent with the 
literature which has found that compared to non-Hispanics, 
Hispanics are 50% more likely to be diagnosed late with HIV 
putting them at a higher risk of being diagnosed with AIDS 
during or soon after diagnosis.
26,27 
 The post-hoc analysis also 
found adherence monitoring to be more common within the 
Hispanic subpopulation compared to the non-Hispanics.  This 
may suggest potential barriers to early detection and the 
need for more emphasis on adherence to ART within this 
population.
1,26,27  
This may present as an opportunity for 
ambulatory care pharmacists, particularly bilingual 
pharmacists, to play an important role in addressing barriers 
that may lead to poor adherence within the Hispanic 
population. 
 
As described earlier, Hispanics represent the fastest growing 
ethnic group in the country and are more likely to be 
uninsured and seek care in free clinics.
14,22,23
  However, there 
is limited literature describing the role of ambulatory care 
pharmacists working in free clinics and with a large Hispanic 
population.
21,28
  Based on the results of this study, 
ambulatory care pharmacists working with HIV patients 
within a free clinic must be well-trained with regards to 
pharmacotherapy and disease state knowledge extending 
beyond HIV.  By working in free clinics, pharmacists are likely 
to serve diverse patient populations.
14  
This may require 
further understanding and recognition of underlying 
language, cultural, economic, access, and psychological 
barriers.  This further highlights the added value of bilingual 
pharmacists and the importance of cultural competency.  
 
One of the limitations of this study was its retrospective, 
cross-sectional design.  The primary outcomes and some 
secondary outcomes were descriptive in nature.  The study 
was not specifically designed to assess outcomes such as 
change in CD4 count, VL, and adherence rate making these 
results more preliminary in nature.  The Department of 
Health and Human Services HIV guidelines recommend 
checking a CD4 count and VL every three months initially.
19 
  
 
Based on this, the duration of the study was relatively short 
for assessing change in CD4 count and VL. As a result, 25% of 
patients seen towards the end of the study time period were 
not included in the analysis because there were no post-
intervention CD4 count and VL documented.   
 
In addition, the ambulatory care pharmacists were only 
present in the TIPS clinic one half day a week.  There were at 
least two and a half other days of clinic during which there 
were no pharmacists present.  A more consistent presence 
during the clinic days would have increased the number of 
patient-pharmacist visits and could have potentially provided 
more data for the primary and secondary analysis.  Also, this 
could have also allowed for a greater number of Hispanic 
patients to be included in the study and during the post-hoc 
analysis in order to better compare the non-Hispanic and 
Hispanic subpopulations. 
 
Conclusion 
This study described the integration and potential role of 
ambulatory care pharmacists working in a multidisciplinary 
team within an HIV clinic in a free and bilingual clinic.  The 
ambulatory care pharmacists in this study went beyond 
adherence monitoring and provided medication review and 
education for both ART and non-ART as well as for HIV and 
non-HIV related co-morbidities.  There is a need for more 
rigorous studies to better determine the impact of 
ambulatory care pharmacists in a free clinic setting on HIV 
patient outcomes. This study was not specifically designed to 
measure differences within the non-Hispanic and Hispanic 
subpopulation.  However, the post-hoc analysis suggests 
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differences between the two groups, which may affect 
patient outcomes.  Further studies are also warranted looking 
closely at the Hispanic population in order to better 
understand the underlying detection and adherence barriers 
and how it can be addressed in order to provide better care 
for the HIV-infected Hispanics living in the US.  
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Appendix A 
 
The Role of Ambulatory Care Pharmacists in an HIV Multidisciplinary Team within a Free and Bilingual Clinic 
 
Data Collection Form 
Patient Demographics and Characteristics 
Gender:   M    F   
Age (at time of first intervention):_________  
Ethnicity:   Caucasian   African-American   Hispanic   Asian   Other: _____________ 
Co-morbidities:  DM   HTN   Dyslipidemia   CHF   Hypothyroidism   Other: ____________________ 
Treatment Naïve:  Yes   No 
Diagnosis of AIDS:  Yes   No 
History of OI or OI prophylaxis:  Yes   No 
Primary Outcome 
Number of Intervention:  Patient education ____ Adherence monitoring ____ Medication review ____ 
Secondary Outcome 
CD4+ cell count (baseline):  ________             CD4+ cell count (post-intervention):  ________    
Viral load count (baseline): _________            Viral load count (post-intervention): ________ 
Adherence rate (baseline): _________          Adherence rate (post-intervention): ________  
ARV complications (baseline): ________          ARV complications (post-intervention): ________  
HIV complications (baseline): ________           HIV complications (post-intervention): ________ 
Missed appointments (baseline): _______        Missed appointments (post-intervention): _______  
Counseled in Spanish:   Yes    No 
Total time of pharmacist-patient contact: ________ 
 
Abbreviations: ARV, antiretroviral; CHF, congestive heart failure; DM, diabetes mellitus; F, female; HIV, human 
immunodeficiency virus; HTN, hypertension; M, male; OI, opportunistic infection 
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Table 1.  Patient Characteristics and Demographics; including Non-Hispanic and Hispanic Subpopulations 
Demographic Study Population 
(n=32) 
 
Non-Hispanic 
Subpopulation 
(n = 25)  
Hispanic 
Subpopulation  
(n=7) 
 
P
a 
Age (years), mean ± SD 46.4 ± 10.2 48.8 ± 9.2 39.9 ± 13.9
 
0.05
b 
Gender (male), No. (%) 20 (62.5) 16 (64) 4 (57) 1.00 
Ethnicity, No. (%)     
     African American 17 (53.1) 17 (68) - -  
     Caucasian 8 (25) 8 (32) - - 
     Hispanic 7 (21.9) - 7 (100) - 
Co-morbid Conditions, mean 
(range) 
4.8 (0-11) 5.4 (0-11) 3 (0-8)  
     Diabetes Mellitus 8 (25) 6 (24) 2 (28.6) 1.00 
     Hypertension 12 (37.5) 9 (36) 3 (42.9) 1.00 
     Dyslipidemia 12 (37.5) 10 (40) 2 (28.6) 0.68 
     Tobacco Use 10 (31.3) 10(40) 0 (0) 0.07 
     Depression 9 (28.1) 8 (32) 1 (14.3) 0.64 
     Hypothyroidism 3 (9.4) 2 (8) 1 (14.3) 0.54 
     Hepatitis B 2 (6.3) 2 (8) 0 (0) 1.00 
Treatment Naïve, No. (%) 13 (40.6) 10 (40) 3 (42.9) 0.56 
Diagnosis of AIDS, No. (%)
 
17 (53.1) 10 (40) 7 (100) 0.01 
Current/History of OI, No. 
(%)
 
13 (40.6) 7 (28) 6 (85.7) 0.01 
Current/History of OI 
Prophylaxis, No. (%) 
20 (62.5) 13 (52) 7 (100) 0.03 
a
P-value based on Fisher Exact comparing non-Hispanic and Hispanic subpopulation, 
b
P-value based on T-test comparing 
non-Hispanic and Hispanic subpopulation  
Abbreviation used:  AIDS, Acquired Immune Deficiency Syndrome; No., number of patients; OI, opportunistic infection; SD, 
standard deviation 
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Table 2.  Primary Endpoint: Pharmacists’ Interventions including Non-Hispanic and Hispanic Subpopulations 
Intervention Study Population (n 
= 32) 
No. (%) 
Non-Hispanic 
Subpopulation  
(n=25) 
 No. (%) 
Hispanic 
Subpopulation  
(n=7) 
No. (%) 
P
a 
Total Interventions 296 211 (71.3) 85 (28.7) - 
Medication Review 198 (66.9) 143 (67.8) 55 (64.7) 0.94 
   Medication Reconciliation 54 (27.3) 39 (27.3) 15 (27.3) - 
   Medication education 21 (10.6) 17 (11.9) 4 (7.3) - 
   Immunization   
   Recommendations 54 (27.3) 36 (25.2) 18 (37.2) - 
   Laboratory Referral 20 (10.1) 16 (11.2) 4 (7.2) - 
   Medication Dosing
b
 48 (24.2) 35 (24.5) 13 (23.6) - 
   Other 1 (0.3) 0 (0) 1 (1.8) - 
Patient Education 69 (23.3) 53 (25.1) 16 (18.8) 0.45 
   Adherence Education 26 (37.7) 17 (32.1) 9 (56.3) - 
   TLC 14 (20.3) 10 (18.9) 4 (25) - 
   Smoking Cessation 17 (24.6) 17 (32.1) 0 (0) - 
   Other 12 (17.4) 9 (17) 3 (18.8) - 
Adherence Monitoring 29 (9.8) 15 (7.1)  14 (16.5) 0.04 
   Medication Box 10 (34.5) 5 (33.3) 5 (35.7) - 
   Medication List for Patient 6 (20.7) 2 (13.3) 4 (28.6) - 
   Prescription Refill Request 8 (27.6) 5 (33.3) 3 (21.4) - 
   Other 5 (17.2) 3 (20) 2 (14.3) - 
a
P-value based on T-test comparing the non-Hispanic and Hispanic subpopulation; 
b
Recommendation to start, stop, or 
change dose of a medication 
Abbreviation used: No., number of interventions; TLC, therapeutic lifestyle changes 
 
 
 
 
Table 3. Secondary Outcome, Including Hispanic Subpopulation
a 
 Study Population  Hispanic Subpopulation 
Outcome Baseline 
Post-
Intervention P
b
 Outcome Baseline 
Post-
Intervention P
b 
CD4 count 
(cells/mm
3
), mean ± 
SD  
(n=24) 
444.2 ± 
249.2 496.4 ± 251.8 0.042 
CD4 count 
(cells/mm
3
), mean 
± SD (n=4) 
374 ± 
270.7 414 ± 222.4 0.44 
VL (copies/mL), 
mean ± SD  
(n=23) 
34,205 ± 
83,262.8 
3,951 ± 
17,410.1 0.061
c 
VL (copies/mL), 
mean ± SD (n=4) 
69, 095 ± 
110,505.0 
21,845 ± 
37,784.7 0.32
c
 
Adherence rate, 
mean % ± SD  
(n=6) 64.2 ± 50.0 97.5 ± 4.1 0.162 
Adherence rate, 
mean % ± SD      
(n=3) 
61.7 ± 
53.9 95.2 ± 5.0 0.39 
a
Only patients with both a baseline and post-intervention value documented for each outcome were included in secondary 
analysis, n indicated for each outcome; 
b
Paired student T-test; 
c
Wilcoxon Signed Rank Test 
Abbreviation used: SD, standard deviation; VL, viral load 
